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Nursing support might help patients with chronic hepatitis C (CHC) remain in good mental and physical 
condition during interferon (IFN) therapy.  However,  the eﬀects of nursing support have not been 
studied adequately in this context.  This case-control study evaluated the eﬀects of nursing support 
during IFN therapy.  Twenty-four CHC patients who received pegylated IFN and ribavirin were 
enrolled.  Nurses advised patients on the maintenance of their mental and physical condition at weekly 
visits,  based on the results of written questionnaires.  An additional 24 patients who received IFN 
therapy without nursing support and who were matched for age,  sex,  platelet count,  viral serogroup 
and IFN regimen were selected with propensity score matching as controls.  The patients with nursing 
support during IFN therapy achieved higher sustained virological responses (79ｵ) than those without 
nursing support (58ｵ).  Adherence to the IFN and ribavirin regimens at 24 weeks of therapy were 
slightly higher in the patients with nursing support than those without it,  but these diﬀerences were not 
statistically signiﬁcant.  Adherence to ribavirin after 24 weeks of therapy was signiﬁcantly higher in 
those with nursing support than those without it (93ｵ and 66ｵ,  p＝0.045).  These results suggested 
that nursing support services could contribute to the virological responses of CHC patients by promot-
ing drug-regimen adherence.
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pproximately 200 million people are infected 
with hepatitis C virus (HCV) worldwide,  and 
many patients with chronic hepatitis C (CHC) may 
have life-threatening diseases such as cirrhosis and 
hepatocellular carcinoma (HCC) without being aware 
of it [1].  Interferon (IFN) is widely used in the treat-
ment of CHC patients,  and the combination treatment 
with pegylated IFN and ribavirin has improved sus-
tained virological response with a success rate of more 
than 50ｵ [2,  3].  However,  IFN has various adverse 
eﬀects,  such as psychological disturbances,  poor 
appetite,  skin rush,  and thrombocytopenia [4].  
According to a systematic review by Bota et al.,  IFN 
treatment was discontinued in 14.5ｵ of patients due 
to severe adverse events.  Therefore,  prevention or 
alleviation of adverse eﬀects is important for IFN 
therapy.
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　 Several studies have reported that good drug 
adherence is needed for sustained virological response 
(SVR) to IFN therapy [5].  Recent reports have pro-
posed that a management program or education by 
medical staﬀ may improve drug adherence [6-9].  The 
outpatient viral hepatitis clinic in our hospital pro-
vides CHC patients with nursing support services 
during IFN therapy; nurses oﬀer face-to-face counsel-
ing,  based on the results of written questionnaires,  at 
the weekly visits for IFN administration,  and advise 
patients on the maintenance of their mental and physi-
cal health.
　 The present study investigated the relationships of 
therapeutic outcomes,  drug adherence and physical 
and mental health to the provision of nursing support 
services in patients during IFN therapy.
Methods
　 Patients. This case-control study included 24 
CHC patients who received combination therapy with 
pegylated IFN and ribavirin at our hospital between 
2010 and 2012.  The viral hepatitis outpatient clinic at 
our hospital provided them with nursing support dur-
ing IFN therapy.  Among the patients who received 
IFN therapy between 2008 and 2010 without nursing 
support,  24 patients,  matched for age,  sex,  platelet 
count,  viral serogroup and IFN regimens,  were 
selected with propensity score matching as a control 
group.  Health-related quality of life,  including both 
mental and physical components,  was evaluated prior 
to therapy for all patients using the 36-item short-
form health survey version 2.  These written question-
naires consist of 8 subscales,  with each subscale 
having been adjusted so that a score of 50 corre-
sponds to the mean value for that subscale in the 
general Japanese population [10].  Patients with liver 
transplantations or co-infection with hepatitis B virus 
or human immuno-deﬁciency virus were excluded.  The 
present study was performed in accordance with the 
Helsinki declaration,  and the protocol was approved 
by the ethics committee of our institute.  All the 
patients provided informed consent.
　 Therapeutic regimens. The therapeutic regi-
mens included weekly subcutaneous administration of 
180µg of pegylated IFN-α2a or 1.5µg per body weight 
of pegylated IFN-α2b plus twice-daily oral intakes of 
ribavirin at a dose based on body weight.  The dura-
tion of IFN therapy was determined based on the viral 
serogroup,  viral load,  and virological response of the 
patients,  for 24 to 72 weeks,  as recommended in the 
guidelines for the management of HCV infection in 
Japan [11].  The doses of IFN and ribavirin were 
individually reduced during the therapy whenever 
needed to lessen adverse eﬀects,  and the dose reduc-
tions were performed according to the labeling.
　 Nursing support services. Each time the 
patients visited the viral hepatitis outpatient clinic for 
IFN administrations during IFN therapy,  they answered 
a written questionnaire assessing their physical condi-
tion with respect to 10 adverse events during IFN 
therapy: increased fever,  body pain,  appetite loss,  
malaise,  eruption,  palpitation,  cough,  dizziness,  sleep 
disturbance,  and anxiety.  Each of these potential 
events was graded using a 5-point scale.  An increase 
in the sum of these scores indicated poorer physical 
condition.  The Beck Depression Inventory of 21 ques-
tions was also used to assess their mental conditions 
[12,  13].  Three nurses,  who received monthly train-
ing via conference on the treatments for liver diseases 
and who each had more than 3 years of experience in 
caring for patients in a hepatitis clinic,  oﬀered face-
to-face counseling to the patients at every visit,  based 
on the results of the written questionnaires.  They also 
provided the patients with further education on their 
liver diseases,  and helped them to maintain their 
motivations for continuing IFN therapy.
　 Statistical methods. Data are expressed as the 
median ± standard error.  Caliper matching was per-
formed on the propensity scores that had absolute 
values less than 10ｵ diﬀerent.  Patient characteris-
tics and changes in mental and physical condition were 
compared between the 2 groups using the Mann-
Whitney U test and Fisherʼs exact probability test.  A 
value of p＜0.05 was considered signiﬁcant.
Results
　 Patient characteristics. Table 1 shows the 
comparisons of patient characteristics between the 
group with and that without nursing support during 
IFN therapy.  Each group consisted of 24 patients 
matched for age,  sex,  platelet count,  viral serogroup,  
IFN regimens,  and history of previous IFN therapy;  
19 patients were male,  and 12 patients (50ｵ) had 
HCV serotype 1.  The median ages were 62 years and 
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60 years,  respectively.  There were no signiﬁcant 
diﬀerences between the 2 groups in terms of hemoglo-
bin levels,  alanine aminotransferase,  or body weight.  
The mental and physical conditions of patients prior to 
IFN therapy were also not signiﬁcantly diﬀerent 
between the 2 groups.
　 Virological response to IFN therapy. Among 
the patients with nursing support during IFN therapy,  
19 patients obtained SVR,  while 3 patients relapsed 
after IFN therapy,  and 2 patients showed partial or 
null virological responses to IFN therapy.  On the 
other hand,  SVR was observed in 14 of the 24 
patients who had no nursing support during IFN 
therapy,  with 5 of the remaining patients showing 
relapse after IFN therapy,  and 5 showing partial or 
null virological responses to IFN therapy.  The patient 
group with nursing support during IFN therapy had a 
slightly higher SVR rate (79ｵ) than the group with-
out nursing support (58ｵ),  but this diﬀerence was not 
statistically signiﬁcant (p＝0.21,  Fisherʼs exact prob-
ability test).
　 Adherence to the IFN and ribavirin regimens 
during IFN therapy. The patients with nursing 
support during IFN therapy exhibited better adher-
ence to their IFN and ribavirin regimens (92ｵ of 
scheduled IFN and 86ｵ of scheduled ribavirin doses) 
than those without nursing support (79ｵ of IFN and 
75ｵ of ribavirin doses),  although these diﬀerences 
were not statistically signiﬁcant.  The patients with 
nursing support during IFN therapy had better drug 
adherence to IFN and ribavirin from 0 to 24 weeks of 
treatment,  and to IFN from 24 weeks and beyond,  
than those without nursing support,  although these 
diﬀerences were not statistically signiﬁcant (p＝0.43,  
p＝0.13,  and p＝0.11,  respectively; Fig.  1).  Drug 
adherence to ribavirin in the latter therapeutic period 
after 24 weeks of IFN therapy was signiﬁcantly 
higher in those with nursing support than those with-
out it (93ｵ,  and 66ｵ,  p＝0.045).
　 Changes in mental and physical condition 
during IFN therapy. Changes in the status of 
physical and mental health during IFN therapy are 
summarized in Fig.  2.  Mental and physical conditions 
were worsened between 12 and 24 weeks of the ther-
apy,  and poor conditions continued thereafter.  The 
changes in mental and physical health status during 
IFN therapy seemed to diﬀer between SVR and non-
SVR patients ; SVR patients had higher scores (i.e.,  
poorer conditions) at baseline,  and showed greater 
increases in their scores during IFN therapy than non-
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Table 1　 Characteristics of the enrolled patients
　　　Patient characteristics
Nursing support
p
＋ －
Age (years) 62±2‡ 60±2‡
Gender (male/female) 19/5 19/5
HCV serogroup (1/2) 12/12 12/12
Therapy regimen (IFN＋RBV/IFN) 21/3 21/3
Platelet count (10000/mm3) 17±1‡ 16±1‡
Hemoglobin (g/dL) 13.6±0.2‡ 13.4±0.5‡ 0.91
Alanine aminotransferase (IU/L) 40±11‡ 45±10‡ 0.55
Body weight (kg) 53±2‡ 56±1‡ 0.55
HCV RNA　(Log IU/mL) 6.3±0.2‡ 6.2±0.1‡ 0.60
　　　Health-related quality of life
Physical function 53±2‡ 53±2‡ 0.94
Role-physical 46±4‡ 49±4‡ 0.74
Bodily pain 54±2‡ 54±2‡ 1.00
General health 45±2‡ 46±2‡ 0.82
Vitality 50±2‡ 49±2‡ 0.87
Social function 44±3‡ 44±3‡ 0.91
Role-emotional 42±3‡ 44±3‡ 0.76
Mental health 44±2‡ 45±2‡ 0.87
‡: Median ± standard error.  HCV,  hepatitis C virus; IFN,  interferon; RBV,  ribavirin.
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Fig. 1　 Adherence to the IFN and riba-
virin regimens during IFN therapy.  The 
percentages of patients complying with 
the IFN and ribavirin treatments during 
IFN therapy were calculated.  The ﬁgure 
expresses the quintiles and medians of 
drug adherence to the IFN and ribavirin 
regimens from 0 to 24 weeks of treatment 
and from 24 weeks and beyond,  respec-
tively,  for the patients with and without 
nursing support during IFN therapy.  NS＋,  
the patients with nursing support during 
IFN therapy; NS－,  the patients without 
nursing support during IFN therapy.
Fig. 2　 Changes in mental and physi-
cal condition during IFN therapy.  
Physical condition was evaluated with a 
physical condition score at every visit for 
IFN injections,  and mental condition was 
assessed by BDI.  The ﬁgures show the 
changes in the mental and physical con-
dition of the patients with nursing support 
during IFN therapy.  EOT,  the end of IFN 
therapy.
SVR patients,  which was consistent with the previous 
report [14].  To clarify this inverse relationship 
between therapeutic outcomes and patient conditions,  
we further investigated the associations between nurs-
ing support and supplemental medications.  Supple-
mental medications consisted only of the drugs for 
additional treatments for side eﬀects during IFN 
therapy.  Our results revealed that the number of 
supplemental drugs by 24 weeks of IFN therapy was 
signiﬁcantly greater among the patients with nursing 
support (11 drugs) than those without it (5 drugs,  
p＜0.01).  The situation was similar thereafter (8 
drugs in the patients with nursing support,  and none 
in those without nursing support,  p＜0.01).
Discussion
　 It was previously reported that nursing support 
during IFN therapy might contribute to virological 
response by improving drug adherence.  However,  the 
precise associations between nursing support and drug 
adherence during IFN therapy have not been studied.  
In the present case-control study,  we enrolled 24 
patients who received IFN therapy with nursing sup-
port,  and compared their therapeutic outcomes and 
drug adherence to those of 24 control patients who 
received IFN therapy without nursing support.  The 
controls were matched with the subject group for 
baseline characteristics with propensity score match-
ing.  The results clariﬁed that precise assessments of 
a patientʼs physical and mental health status by a nurse 
may help in the maintenance of drug adherence when 
the patients suﬀer from poor mental condition,  and 
thus nursing support may improve the virological 
responses of CHC patients.
　 Previous studies have suggested that education on 
IFN therapy by a specialized nurse or a medical staﬀ 
member increases the virological response of CHC 
patients,  particularly diﬃcult-to-treat patients [6-9].  
However,  these studies have not clariﬁed the associa-
tions between nursing support services and either drug 
adherence or other therapy-associated factors.  Through 
the observation of patients who received nursing sup-
port services during IFN therapy,  we found that SVR 
patients had worse mental and physical health status 
during IFN therapy than non-SVR patients.  This is 
important,  since it has been reported that patients 
sometimes reduce or stop drug administration when 
they feel worse [15].  Continuously worsening condi-
tions thus might pose a risk of lowered drug compli-
ance.  Nursing support can help patients to better 
understand the side eﬀects of their drugs and the 
necessity of good drug compliance.  An improved 
understanding of their liver diseases may encourage 
patients to more clearly explain any unpleasant eﬀects 
they are experiencing.  This,  in turn,  would enable the 
precise assessment of individual patients by nurses,  
and the supply of appropriate supplemental medica-
tions by doctors.  Our results revealed that the num-
ber of supplemental drugs was signiﬁcantly greater 
among the patients with nursing support during IFN 
therapy than those without it,  and suggested that the 
administration of supplemental drugs to alleviate 
adverse events is helpful to maintain adherence to the 
IFN and ribavirin regimens.
　 The number of patients was limited in the present 
study,  and we could not verify the impact of nursing 
support in comparison with other factors aﬀecting 
therapeutic outcomes such as host and viral factors 
[14,  16,  17].  The impact of nursing support should 
be explored in future large scale studies.
　 In conclusion,  the present study revealed that 
precise assessments of the mental and physical condi-
tion of individual patients by a nurse might promote 
maintenance of a drug regimen in cases where such 
conditions are poor.  Nursing support might thereby 
contribute to the virological responses of CHC 
patients by promoting continued drug compliance.
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